The dividend declaration and record-high H1 2026 results confirm Kamada is executing on its growth strategy and generating strong cash flow. Traders should watch for the full H1 2026 financial details in the next filing to validate the revenue and EBITDA trajectory against the FY2026 guidance. The ex-dividend date (Aug 27) may create a minor arbitrage opportunity.
Drugs in focus
KMDA drug pipeline →CYTOGAM
● Neutral Named in this 6-K- Impact
- Phase
- Approved
- Time to market
- Already FDA-approved and commercially marketed
- Next catalyst
- None dated
What to watchCYTOGAM contributes ~12-13% of Kamada's total revenue (~$22.5M in 2024) and is growing 31% YoY, but is not a binary catalyst for the stock. Watch Q2 2026 earnings (~Aug 12, 2026) for CYTOGAM sales trajectory and any updates on the SHIELD study. The stock's primary drivers are Glassia (alpha-1 antitrypsin) and KEDRAB (rabies IG), which represent larger revenue streams.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 17 $7.76entry
- T+1 · 3mo ago +1.68%α +2.35% · $7.89
- T+5 · 3mo ago +8.63%α +9.82% · $8.43
- T+20 · 2mo ago +4.25%α +6.23% · $8.09
- T+60 · 7d ago +4.38%α +7.33% · $8.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kamada Ltd. reported record-high revenue and profitability for the first six months of 2026 and declared a cash dividend of $0.17 per share (totaling ~$9.8 million), payable September 17, 2026. The dividend, consistent with the company's policy, signals strong cash generation and management's confidence in the business outlook. The filing also references a prior 20-F annual report that guided for FY2026 revenue of $200M-$205M and adjusted EBITDA of $50M-$53M, representing ~13% and ~23% YoY growth respectively at the midpoint, providing a positive context for the dividend announcement.
Key Facts
- Kamada declared a cash dividend of $0.17 per share, totaling approximately $9.8 million.
- The dividend is payable on September 17, 2026, to shareholders of record on August 27, 2026.
- The company reported record-high revenue and profitability for the first six months of 2026.
- The prior 20-F (March 2026) guided for FY2026 revenue of $200M-$205M and adjusted EBITDA of $50M-$53M.
- FIMI Opportunity Funds is the controlling shareholder, beneficially owning approximately 38% of outstanding shares.
Financial Impact
Dividend of $9.8M (~2.2% of market cap) signals strong cash flow. Prior FY2026 guidance implies ~13% YoY revenue growth and ~23% YoY adjusted EBITDA growth at midpoint.
Risk Factors
- Geopolitical risk from conflicts in the Middle East and Israel.
- Potential impact of tariffs on international trade and sales/profit levels.
- Execution risk in M&A, biosimilar launches, and plasma collection ramp-up.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 11 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (KMDA), Batch item 1 | 0001213900-26-090473 |
| Document: ea030232701ex99-1.htm | 0001213900-26-090473 |
| Document: 0001213900-26-090473-index-headers.html | press-3345953 |
| Document: 0001213900-26-090473-index.html | 0001213900-26-090473 |
| Document: 0001213900-26-090473.txt | 0001213900-26-090473 |
| 6-K Filing (KMDA), Batch item 6 | 0001213900-26-090473 |
| Document: ea030232701ex99-1.htm | 0001213900-26-090473 |
| Document: 0001213900-26-090473-index-headers.html | 0001213900-26-090473 |
| Document: 0001213900-26-090473-index.html | 0001213900-26-090473 |
| Document: 0001213900-26-090473.txt | 0001213900-26-090473 |
| PRESS-RELEASE Data (Synthetic) | 0001213900-26-090473 |
Track record
25 reports on KMDA
7 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +16.13% at T+20 after the Aug 12, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 9, 20267d ago 6-K Bullish 6/10 No price data
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
- Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
- Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
- Sep 10, 20269w ago 6-K Neutral 2/10 Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
- Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers